Stress Response and Artemisinin Resistance in Malaria Parasite

Abstract

Malaria control programs have reduced disease incidence worldwide by 50% since the year 2000, avoiding an estimated 3.3 million deaths worldwide. Cornerstones of this success are ACTs (artemisinin combination therapies), a drug combination that is highly effective against the malaria parasite. Unfortunately, recent reports from Southeast Asia have indicated the appearance of ACT-resistant parasites. In order to contain the spread of drug-resistant malaria parasites, we urgently need to develop new drugs to include in combination therapies to provide a second line of defense against the malaria parasite in case of ACT failure. Our project proposes to study a pathway that is activated in ACT-resistant malaria parasites. If our hypothesis is correct and this pathway allows the parasite to overcome the ACTs lethal effects, we would have identified a therapeutic target to develop new antimalarial drugs. The inhibition of this pathway would help contain the spread of ACT-resistant malaria parasites, and it will cement our gains against the disease.

Document Details

Document Type
DoD Grant Award
Publication Date
Jan 31, 2017
Source ID
W81XWH1610241

Entities

People

  • Juan Pizarro

Organizations

  • Tulane University of Louisiana
  • United States Army

Tags

Fields of Study

  • Medicine

Readers

  • Oncology (Cancer Research).
  • Parasitology and Pharmacology of Malaria.